Cannabis investors have been on a rollercoaster ride this year, with COVID-19 fundamentally changing the sector. Staring into the second half of 2020, what kind of metrics should market participants look for?

Nawan Butt, portfolio manager with Purpose Investments, told the Investing News Network (INN) that among other things he’s been drilling down on key balance sheet numbers. He noted that in the Canadian marijuana sector, attention is shifting to the sales performance of public producers.


He’s also been examining the value of the cannabis brands put forth by these companies. Read on for a closer look at what Butt wants to see among marijuana companies right now.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Balance sheets and achieving profitability

Sales have been in focus as the novel coronavirus has spread across Canada. While COVID-19 has ramped up the struggles seen by public cannabis names, it has also brought much-needed solid movement in retail sales of recreational product across the country.

Recreational cannabis sales in Canada have been varied during the outbreak, but on Wednesday (July 24), Statistics Canada confirmed that sales for the month of May upended those of April by over 4 percent. The total for May was just under C$186 million.

Speaking about performance, Butt said that the pressure on cannabis companies has heightened thanks to the economic impact and investment complications seen from the reaction to COVID-19. He said he’s been dedicating a lot of attention to the balance sheets of public cannabis companies in order to really see the strength of their presence and if they are ready to survive further tension.

“For these producers, the current year or the second half of the year really depends on getting to profitability, and getting to profitability is going to be a large battle in the deep-value space,” Butt said.

The Q2 2020 period for cannabis highlighted the shifts in thinking surrounding the cannabis opportunity.

At a recent online investor forum, Alan Brochstein, marijuana analyst and industry commentator with 420 Investor and New Cannabis Ventures, said cannabis investment stories are beginning to be rewarded for simplicity. That’s compared to earlier, when more complex operations were valued.

Butt told INN he evaluates the various licensed producers (LPs) in Canada by grouping them by distinctive metrics and comparing them.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

“For instance, LPs that have balance sheet strengths, we put them up against each other and we take a look at their multiples … LPs that have distressed balance sheets, we take a look at those together. LPs with smaller footprints, more specialized products, we take a look at those together,” he said.

Cannabis investments have grown to the point where a blanket statement of performance no longer works; instead, investors have to really evaluate the different sizes and opportunities attached to these companies and compare them to the respective groupings they belong in, according to Butt.

Brands struggling to catch on with consumers

Butt said brand competition will be key particularly when it comes to value options and the ability to sell large volumes of cannabis product from producers.

“That deep value is essentially going to subsidize any operations that go on for the higher-margin products that they’re taking a look at,” the expert said.

However, brands in Canada have not really made an impact in the minds of consumers. A recent report from the Brightfield Group shows that no current active brand in the country has a higher recognition factor than 41 percent, with most averaging between 1 and 15 percent only — a tough blow for the marketing and promotion done by the cannabis industry so far.

The data from the researchers shows that when it comes to actual purchase decisions, consumers will pick products based on price.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less